Georg Boonen – CEO, Max Zeller
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. In 2016 Celgene celebrated 10 years of Switzerland as the EMEA regional headquarters. Their workforce has increased from literally a handful of individuals in 2006 to 700 in Switzerland now and 2,300 across Europe. The EMEA International Headquarters in Boudry includes global manufacturing, clinical R&D, drug safety, regulatory, medical affairs and marketing along with shared services like human resources, legal and finance.
Contact
Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping…
A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines;…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on…
Once a quiet legacy player in dermatology, LEO Pharma is re-emerging with renewed focus and ambition under CEO Christophe Bourdon. With global leadership experience at Amgen and Alexion, Bourdon is…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Writing in ISPOR’s Value and Outcomes Spotlight magazine, Beth Fand Incollingo looks at why health economics and outcomes research may hold the key to solving some of healthcare’s most entrenched…
Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the…
Saudi Arabia’s pharmaceutical sector continues its impressive growth leadership within the region. With a 9.1 percent market growth in 2024 and a projected USD 11.6 billion in sales, the Kingdom…
After February’s snap election that brought Friedrich Merz to power, a coalition between his conservative CDU/CSU bloc and the centre-left SPD has outlined an agreement this month that will serve…
We’re not just building facilities—we’re building the future of medicine, where innovation is inclusive, access is equitable, and every breakthrough brings us closer to a healthier world. Biopharmaceutical innovation is…
While on the surface it may look like pharmaceuticals have been spared by Donald Trump’s “Liberation Day” trade policies, drugmakers still lack a clear picture of how they will be…
See our Cookie Privacy Policy Here
